Current practices in clinical neurofeedback with functional MRI – Analysis of a survey using the TIDieR checklist.

Elizabeth Randell\textsuperscript{1}, Rachel McNamara\textsuperscript{1}, Leena Subramanian\textsuperscript{2,3}, Kerenza Hood\textsuperscript{1}, David Linden\textsuperscript{2,3}.

1. Centre for Trials Research, Cardiff University, Neuadd Meirionnydd, Heath Park, Cardiff, UK.

2. Division of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Hadyn Ellis Building, Maindy Road, Cardiff, UK.

3. Cardiff University Brain Research Imaging Centre, School of Psychology, Cardiff University, Maindy Road, Cardiff, UK.

$ Corresponding author. Randelle@cardiff.ac.uk
Abstract

Background: A core principle of creating a scientific evidence base is that results can be replicated in independent experiments and in health intervention research. The TIDieR (Template for Intervention Description and Replication) checklist has been developed to aid in summarising key items needed when reporting clinical trials and other well designed evaluations of complex interventions in order that findings can be replicated or built on reliably. Neurofeedback (NF) using functional MRI (fMRI) is a multicomponent intervention that should be considered a complex intervention. The TIDieR checklist (with minor modification to increase applicability in this context) was distributed to NF researchers as a survey of current practice in the design and conduct of clinical studies. The aim was to document practice and convergence between research groups, highlighting areas for discussion and providing a basis for recommendations for harmonisation and standardisation.

Methods: The TIDieR checklist was interpreted and expanded (21 questions) to make it applicable to neurofeedback research studies. Using the web-based Bristol Online Survey (BOS) tool, the revised checklist was disseminated to researchers in the BRAINTRAIN European research collaborative network (supported by the European Commission) and others in the fMRI-neurofeedback community.

Results: There were 16 responses to the survey. Responses were reported under eight main headings which covered the six domains of the TIDieR checklist: What, Why, When, How, Where and Who.

Conclusions: This piece of work provides encouraging insight into the ability to be able to map neuroimaging interventions to a structured framework for reporting purposes. Regardless of the considerable variability of design components, all studies could be
described in standard terms of diagnostic groups, dose/duration, targeted areas/signals, and psychological strategies and learning models. Recommendations are made which include providing detailed rationale of intervention design in study protocols.

Keywords: Psychiatric disorder; Neuroimaging; fMRI.
Introduction

A core principle of creating a scientific evidence base is that results can be replicated in independent experiments and in clinical trials and other well designed studies of interventions that aim to improve health outcomes. It is also important that interventions are described in enough detail for them to be implemented in practice when shown to be effective. For an evaluation of a drug, this standardisation of the intervention is achieved through a formal quality control process in production and release and documented in an investigator’s brochure. Non-pharmacological interventions cannot be standardised in the same way with chemical descriptors, and as they become increasingly complex it has been recognised that we need to improve the way in which they are developed, specified and quality controlled. The Medical Research Council guidance on complex intervention development and evaluation[1] highlights the importance of developing interventions with a strong theoretical underpinning, and modelling potential processes and outcomes. This has led to the increased use of logic models, borrowed from programme theory[2], which are frameworks used to conceptualise the components of a complex intervention and the pathways by which it achieves its outcomes. As well, it has seen the development of the TIDieR (Template for Intervention Description and Replication) checklist which summarises the key items needed when reporting clinical trials and other well designed evaluations of complex interventions in order that findings can be replicated or built on reliably[3].

The TIDieR checklist summarises 12 items which should be reported under the six domains of What, Why, When, How, Where and Who. These draw out a detailed description of

*What* is done as part of the intervention (including materials and process), *Why* it is done (including underlying theory), *When* (and how often and how much), *How* it is done
(including mode of delivery), Where (location and infrastructure) and Who (who delivers the components, what is their skill set and training). Other items also include the degree to which all of the above can be tailored for an individual setting or patient, and intended and actual quality of delivery targets (fidelity). Whilst the TIDieR checklist is intended to improve the reporting of complex interventions, it can also be utilised to explore potential variation in intervention definition and delivery (i.e. between participants, or across settings), which may otherwise be insufficiently captured. Understanding areas of commonality and difference should contribute to the discussion and debate as to what an intervention is, how it should be defined and how much adaptation or variation is appropriate.

Neurofeedback describes a group of technologies that involve real-time processing of brain signals to provide feedback to participants and train them in the self-regulation of the targeted brain signal[5]. Neurofeedback with electroencephalogram (EEG) signals has a long tradition in psychiatric research and an established group of clinical practitioners although the evidence for even its most popular application in the treatment of attention deficit/hyperactivity disorder is mixed [5]. A meta-analysis found significant effects of EEG-neurofeedback on both parent- and teacher-rated assessments[6], but a recent RCT found no benefit for real compared to sham EEG-NFT on self-reported ADHD symptoms[7]. Neurofeedback with functional magnetic resonance signals (fMRI) is a more recent field of technological development[8], but has recently seen a marked increase in clinical interest, particularly from the psychiatric side[9]. A search on clinicaltrials.gov, a widely used trials registration database, conducted on 22 August 2017 with the search terms “fMRI” and “neurofeedback” yielded 33 trials using fMRI-based neurofeedback, most of them ongoing, in psychiatric and neurological diseases and chronic pain. These trials are generally rather
small and represent the early stages of treatment development. They are also characterised by a considerable heterogeneity in terms of the clinical populations studied, target areas and systems in the brain, dosage (how many training sessions), duration, outcome measures and control conditions. Another indicator of increasing work in this area is relevant publications found with search terms “fMRI” and “neurofeedback” for 2011 and 2016: 15 papers in 2011; 43 in 2016.

Neurofeedback using fMRI is a multicomponent intervention that should be considered a complex intervention. As such, best practice would be to use appropriate reporting standards already in place for such interventions. Here, we report on the first application of a TIDieR checklist to neurofeedback. Minor modifications were made to TIDieR, to include additional items that captured the specific requirements of neurofeedback (for example, specification of targeted brain signals) and its application to document the growing field of fMRI-based neurofeedback.

A field like neurofeedback, in which presently most trials have relatively low numbers of patients (in the low teens, in the case of most fMRI-neurofeedback trials) and which is applied across a wide range of psychiatric and neurological diseases, is particularly dependent on standardised intervention delivery and reporting in order to minimise inter-trial and inter-site variability and enable the meta-analyses that will be crucial to provide reliable evidence on its efficacy. As a first step it is important to establish where commonalities lie within this research, which was one of the aims of the present study. We also wanted to highlight areas for discussion and provide a basis for recommendations for harmonisation and standardisation.
Method

The standard 12 item TIDieR checklist (Appendix A) was reviewed by the authors to establish whether it might potentially be applicable to neurofeedback (NF) research studies. It was agreed that wording in the checklist needed to be refined to make it more specific to NF interventions. After several rounds of discussion and review, consensus was reached by the authors that the main TIDieR checklist domains (What, Why, When, How, Where and Who) would be applicable but with some additional clarifications (Table 1). For example, one such clarification related to control conditions/groups (Heading 2). Authors of the TIDieR checklist[3] recommend that the checklist is completed separately for control conditions however, including it in our adapted NF specific checklist could help in understanding what responders consider effective and ‘inert’ aspects of the intervention.

Once consensus on the content of the checklist was reached, it was laid out as a web-based survey which could then be sent to the international NF research community. The Bristol Online Survey (BOS) tool was ideal to use for this small scale piece of online research as it allowed the authors to design a dedicated webpage where the survey could be completed. All questions in the survey were designed to illicit descriptive responses.

Table 1. NF checklist survey questions sent to the NF research community using the BOS tool.
<table>
<thead>
<tr>
<th>ITEM</th>
<th>HEADING AND QUESTION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HEADING 1: MATERIALS</strong></td>
<td></td>
</tr>
</tbody>
</table>
| 1. | What materials do you use as part of the intervention?  
(Please distinguish which are used for delivering the intervention and which are for training intervention providers.) |
| 2. | What machine and software do you use? |
| 3. | What is the neurofeedback interface? |
| **HEADING 2: PROCEDURES** | |
| 4. | Please describe each of the procedures, activities, and/or processes used in the intervention. We are interested in all of the components that go into the intervention. |
| 5. | What control conditions/ groups are used? |
| 6. | How do you define a “placebo” intervention for neurofeedback? |
| **HEADING 3: PROVISION AND TRAINING** | |
| 7. | Who provides the different elements of intervention? |
| 8. | What training/expertise do they require to deliver the different components of their intervention? |
| 9. | Is there ongoing quality assurance/supervision and if so from whom? |
| **HEADING 4: HOW** | |
| 10. | Which areas/ networks/ signals of the brain are targeted? |
| 11. | How are patients taught to target this area? |
| 12. | How are individual mental strategies documented? |
| **HEADING 5: WHERE** | |
13. Where is the intervention delivered? Please include any necessary infrastructure or relevant features.

**HEADING 6: WHEN AND HOW**

14. In how many sessions is the intervention delivered?

15. How long do the sessions last?

16. Over what period of time?

17. Do you incorporate any homework and, if so, what are its components?

**HEADING 7: TAILORING**

18. What adaptations or modifications are made to the intervention in order to personalise it?

**HEADING 8: FIDELITY**

19. Do you measure intervention adherence or fidelity?

20. How do you measure this?

21. Average rate of patients dropping out in the course of the intervention?

A link to the unique BOS webpage was sent to 14 partners working on BRAINTRAIN collaborations at 10 different institutions. The EU funded BRAINTRAIN collaboration includes seven proof of principle early studies in different clinical populations[10]. The main objective of the collaboration is to ‘improve and adapt methods of real-time fMRI-NF for clinical use, including the combination with electroencephalography (EEG) and the development of standardised procedures for the mapping of brain networks that can be targeted with neurofeedback’[11]. In addition, five other researchers known to be carrying out work in this area were also sent the link along with those subscribed to an international mailing list used by the fMRI-neurofeedback community (rtFIN@utlists.utexas.edu). The link
was available from the 30th June 2017 until the 14th August 2017 (45 days). Once closed, survey responses were extracted and examined for commonalities by the authors.

Results

There were 16 responses to the survey (Appendix B). Responders work in the clinical areas of depression (x4), obsessive compulsive disorder, alcohol dependence (x2), chronic pain (x2), Huntington’s disease, eating disorders, schizophrenia, ADHD (x2), post-traumatic stress disorder (PTSD) and Borderline Personality Disorder (BPD). 14 responders reported on fMRI-protocols, one on an MEG (magnetoencephalography) based protocol, and one group combines fMRI and EEG in their neurofeedback delivery. All responses have been summarised under heading titles.

Heading 1: Materials.

These questions were designed to identify whether common materials, software and equipment are used among researchers. The responses to ‘what materials do you use as part of the intervention?’ were very varied and perhaps the question was not interpreted as intended. Some responses were to list the outcome measures provided to participants. The aim of the question was to establish how participants as well as those delivering interventions are provided with enough information to be able to carry out intervention tasks. Responses indicated that the majority relied on the study protocol rather than detailed user manuals for details of how to carry out the intervention. Only three responders explicitly reported use of manuals or standard operating procedures developed for delivery of the intervention.
Responses to the questions of software and interface were more clear and it was apparent that this could be answered succinctly by researchers.

**Heading 2: Procedures.**

As described earlier, the authors wanted to ensure that not only could intervention procedures be detailed, but also those in any control conditions, the exact nature of which are rarely described fully. Groups described their means of identifying target brain areas, systems for delivering feedback, neurofeedback protocol (timing of regulation and rest/control blocks) and some of the strategies provided where applicable.

Feedback was always visual and delivered in one of three ways, using an analogue representation (e.g., thermometer) of activation levels, or a change of stimulus properties (e.g., size of an alcohol-related picture) based on activation level, or a combination of a disease-relevant visual cue (e.g., alcohol- or food-related picture) and an analogue representation. Thus participants either have to regulate their brain activity whilst they are only watching the changing feedback signal, or they have to regulate their brain activity whilst watching a disease-relevant cue, and feedback is provided either directly through this cue (changing size) or with an additional signal appearing next to the cue.

One group working with adolescents reported using a token system, under which participants’ actual financial reward depended on the number of successful neurofeedback trials.

Use of control conditions varied according to study design and commonly included sham treatment groups, upregulation of a different target area, or treatment as usual, but also
psychological interventions not involving scanning. Definitions of ‘placebo’ were mostly
described as ‘sham feedback’ or ‘active control neurofeedback of another region’. Two
ways of implementing sham feedback were described, through use of a random activation
time course or through yoked feedback which uses the signal from another participant).

**Heading 3: Provision and training.**

All responses show that the intervention is typically delivered by either post-graduate
(Masters or Doctoral students) or post-Doctoral researchers. In line with this, those
delivering the intervention will have had considerable academic and practical experience of
using appropriate technologies and perhaps relatively little clinical experience. Although
perhaps not entirely relevant to descriptions of interventions, none of the responders listed
having had specific training in clinical trials.

The use of standard operating procedures (SOP) was reported. SOPs were being used to
supplement experience and to specify exact working practices for using the scanning
equipment.

Quality assurance (QA) and supervision tended to be provided by Principal investigators and
senior members of the research team. Areas covered by QA and supervision included
scanning procedures, participant handling and data quality which covered mainly the
handling of imaging rather than psychometric data. The frequency of QA/supervision varied
from session by session feedback to monthly observations. A couple of researchers reported
that no QA or supervision was provided or that it was very informal.
Heading 4: How.

Targeted areas of the brain were well described (incorporating information from question 4). The groups used either structurally or functionally defined regions of interest. The definition of structural areas was through anatomical labelling (e.g., amygdala, ventral striatum) whereas functionally defined areas were identified through a preceding localiser scan employing fMRI during exposure to stimuli relevant to the targeted neuropsychological process, for example contrasting alcohol cues vs. neutral visual stimuli or pain-catastrophising vs. neutral statements. Of the groups using structurally defined target areas four reported targeting the amygdala (albeit varying between uni- and bilateral localisation) but otherwise there was no overlap in structural or functional localisers. Studies also varied in whether they requested participants to up- or downregulate activity in the target areas, or whether they used correlation coefficients or other measures of functional relatedness/connectivity as target signals.

In response to whether patients were taught to target specific areas of the brain, participants were mainly encouraged to identify their own strategies through learning phases. Also adducing information from question 4, eight out of 16 responders reported providing instructions or guidance (or at least some information about the target area from which they could infer useful strategies) to participants as summarised in Table 2.

Table 2. Methods of targeting brain areas.

<table>
<thead>
<tr>
<th>Response number</th>
<th>Q11. How are patients taught to target this area?</th>
</tr>
</thead>
</table>


1. Contemplate positive autobiographical memories.

2. Feedback is provided by varying the size of the target picture. Participants are instructed to use whatever mental strategies are at their disposal to alter the size of the image.

3. Participants are given psychological strategies to choose from.

4. Participants are guided by the feedback signal. Most often we also provide written strategy suggestions that they can (but don't have to) try.

5. In the training sessions, participants learn to self-control the activity of the dorsolateral prefrontal cortex. The idea of neurofeedback (self-regulation) is explained and suggestions to control the specific brain areas with reappraisal techniques are given.

6. On the first two sessions we encourage implicit learning by trial and error. The given task is to influence the feedback using some mental strategy. From session three onwards, we suggest individual tailored strategies based on our experience.

7. Subjects were instructed to regulate “the feeling center” of their brains and were told that this brain region is involved in the “perception and processing of emotions”.

8. Using motor imagery as a starting point and then adapting their strategy using trial and error.

All responders reported using post treatment questionnaires and interviews to allow participants to identify the strategies they had used during the intervention.
**Heading 5: Where.**

Interventions were delivered in research facilities located in either universities or academic hospital research centres. Specialist scanning facilities and clinic spaces were commonly listed as venues.

**Heading 6: When and how.**

Responders were able to report the specific number of runs and sessions used in the intervention. All interventions were fairly brief with little variation across them in terms of length. 13 groups reported running up to five sessions and just three groups reported running between six and 17 sessions. Feedback runs were reported to last between one and 10 minutes. Sessions ranged little in length and averaged at about an hour long. The period of time sessions were spread over also varied and averaged at 2 weeks for all sessions.

The majority of researchers (nine of 14 responses) reported that they do not incorporate homework elements into their studies. Five confirmed that while homework was not a formal task, they encouraged participants to apply their training strategies in real life conditions.

**Heading 7: Tailoring.**

Nine responders reported elements of tailoring to individual patients. These elements included individual definition of target areas through functional localisers, adjustment of difficulty to participants’ self-regulation success rates (shaping) and use of visual stimuli that
were adapted to the patient’s clinical situation (e.g. alcohol cues reflecting their drinks preferences).

**Heading 8: Fidelity.**

Of the 15 responses to questions under this heading, five researchers reported that they do not measure adherence or fidelity, 10 reported that they do. Distinction was not made between adherence and fidelity.

Six researchers reported using questionnaires to measure adherence or fidelity; four used visual confirmation that participants were completing tasks as desired and two reported that attendance rates and homework adherence were monitored. Average dropout rates were listed in percentages from 0% to 30%.

**Discussion**

From the responses to the TIDieR checklist survey, this piece of work provides encouraging insight into the ability to be able to map neuroimaging interventions to a structured framework for reporting purposes. Regardless of the considerable variability of design components, all studies could be described in standard terms of dose/ duration, targeted areas/ signals, and psychological strategies and learning models. In addition to more general questions that capture parameters across complex interventions (e.g. training status of the person delivering the intervention; number of sessions) we included several neurofeedback-specific questions (2, 3, 6, 10-12) that allowed investigators across signal modalities (mainly fMRI but also EEG and MEG) to capture the neurophysiological principles of their procedures. Although not included in the survey as a specific question, it was also possible for researchers to add in detail to describe the diagnostic groups they work with.
This information is useful to capture and could be explicit in any future use of the checklist. Similar NF interventions could potentially be applied to different diagnostic groups (e.g. an alcohol cue paradigm could be modified to address eating disorders, pathological gambling, drug addictions etc.).

Some interesting topics were highlighted by the survey: it is notoriously difficulty to design “placebo” conditions for complex interventions. Because it is impossible for these conditions to be psychologically inert one should probably call them “control” rather than “placebo” conditions. In the survey responses, comparators included protocols of sham feedback, upregulation of a different target area, a psychological intervention not involving scanning, and treatment as usual (TAU). All of these have been used in published trials and protocols, yoked feedback[12], target area in parietal lobe as control for amygdala neurofeedback[13], other interventions, matched for time/ intensity[14,15], Treatment as Usual (TAU)[10]. They all have advantages and disadvantages, and the variability in trial designs highlights the experience that there is no ideal control condition for neurofeedback. Comparing a neurofeedback intervention with TAU is useful if the aim is to determine whether any additional clinical benefits can be expected and whether further, larger scale effectiveness trials are justified. However, this comparison does not differentiate between the many potential mechanisms that can lead to positive effects of neurofeedback, which include the experience of the high-technology environment, the time and effort of researchers, the experience of self-control/ self-efficacy and the experience of reward, in addition to any direct physiological effects of the self-regulation. They match non-scanning intervention controls for non-specific investigator effects and general training effects, but not for any of the NF-specific components. A neurofeedback intervention targeting a
different area, which is not obviously involved in the neuropsychological process supposed to underlie the expected therapeutic benefit, is probably the tightest experimental control in current use, but has its own challenges[16,17]. It may be too conservative if it turns out that the targeted area is, in fact, involved in the process (for example a control area in sensorimotor cortex in a depression trial may still be relevant to emotion processing), and it will be challenging to adjust the target and control area for self-regulation difficulty (which is needed in order to match the interventions for reward experience). Finally sham feedback (yoked feedback from another participant or random feedback) controls for training effort and the neurofeedback environment but differs from the real feedback in terms of the experience of self-efficacy and can potentially frustrate participants by providing low reward levels and/or a false sense of control[18].

Although this information was not specifically requested as part of the BOS, the authors would like to invite the community to think about including the rationale for their intervention design within study protocols. This would include being more explicit about the reasons behind the length and dose of any given intervention as well as details of any theories or mechanisms underlying the choice of brain regions being targeted and interfaces being used. Researchers may also want to think about the use of intervention handbooks and methods of standardising instructions for delivery of interventions, for participants and the researchers themselves, but also to enable replication by other research teams. This might also include formal ways of issuing homework where it is set. Using such tools could aid further understanding of intervention fidelity, that is to say whether or not the content of the intervention was delivered and received as it should be. This may be something different to adherence to the study protocol.
Our findings highlight the appropriateness and suitability of using a checklist based on the TIDieR to report, evaluate and design neurofeedback interventions. They also document a considerable variability in the neuropsychological and neurophysiological processes targeted with neurofeedback, in the ways in which feedback is delivered, in the amount of instructions provided and individual tailoring and in the dosage and duration of the intervention. This is to be expected in an emerging field of therapeutic research but highlights the need for standardisation and harmonisation of neurofeedback interventions. Such a focus on definition and clear reporting will also potentially increase the speed of development of this intervention as the field moves on towards larger and definitive clinical trials.

**Funding**

BRAINTRAIN is funded by the European Commission 7th Framework Programme for Research, Technological Development and Demonstration under the Grant Agreement n° 602186. The Centre for Trials Research is funded by Health and Care Research Wales.

**Disclosure of interests**

There are no conflicts of interest.

**Vitae**

Elizabeth Randell is a Research Associate and Trial Manager at the Centre for Trials Research, Cardiff University.
Dr Rachel McNamara is a Senior Research Fellow and Deputy Director for Mind, Brain & Neuroscience Trials at the Centre for Trials Research, Cardiff University.

Dr Leena Subramanian is a Postdoctoral researcher in the Division of Psychological Medicine and Clinical Neurosciences at Cardiff University.

Professor Kerenza Hood is a statistician and Director of the Centre for Trials Research at Cardiff University.

Professor David Linden is Clinical Professor in the Division of Psychological Medicine and Clinical Neurosciences at Cardiff University.

References:


## Appendix A: TIDieR Checklist

<table>
<thead>
<tr>
<th>ITEM</th>
<th>HEADING AND QUESTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Provide the name or a phrase that describes the intervention.</td>
</tr>
<tr>
<td>2.</td>
<td>Describe any rationale, theory, or goal of the elements essential to the intervention.</td>
</tr>
<tr>
<td>3.</td>
<td>Materials: Describe any physical or informational materials used in the intervention, including those provided to participants or used in intervention delivery or in training of intervention providers. Provide information on where the materials can be accessed (e.g. online appendix, URL).</td>
</tr>
<tr>
<td>4.</td>
<td>Procedures: Describe each of the procedures, activities, and/or processes used in the intervention, including any enabling or support activities.</td>
</tr>
<tr>
<td>5.</td>
<td>For each category of intervention provider (e.g. psychologist, nursing assistant), describe their expertise, background and any specific training given.</td>
</tr>
<tr>
<td>6.</td>
<td>Describe the modes of delivery (e.g. face-to-face or by some other mechanism, such as internet or telephone) of the intervention and whether it was provided individually or in a group.</td>
</tr>
<tr>
<td>7.</td>
<td>Describe the type(s) of location(s) where the intervention occurred, including any</td>
</tr>
</tbody>
</table>
necessary infrastructure or relevant features.

**WHEN and HOW MUCH**

8. Describe the number of times the intervention was delivered and over what period of time including the number of sessions, their schedule, and their duration, intensity or dose.

**TAILORING**

9. If the intervention was planned to be personalised, titrated or adapted, then describe what, why, when, and how.

**MODIFICATIONS**

10. If the intervention was modified during the course of the study, describe the changes (what, why, when, and how).

**HOW WELL**

11. Planned: If intervention adherence or fidelity was assessed, describe how and by whom, and if any strategies were used to maintain or improve fidelity, describe them.

12. Actual: If intervention adherence or fidelity was assessed, describe the extent to which the intervention was delivered as planned.

**Appendix B: Survey contributors**

Those who contributed to the BOS agreed to provide their names in order for us to acknowledge their contribution to this piece of work.

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
<th>Acknowledgments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Katya Rubia</td>
<td>Kings College London,</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Location</td>
<td></td>
</tr>
<tr>
<td>---------------------------</td>
<td>---------------------------------</td>
<td></td>
</tr>
<tr>
<td>Kymberly Young</td>
<td>England</td>
<td></td>
</tr>
<tr>
<td>Jeungchan Lee</td>
<td>University of Pittsburgh, USA</td>
<td></td>
</tr>
<tr>
<td>David Linden and Miles Cox</td>
<td>Cardiff University, Wales</td>
<td></td>
</tr>
<tr>
<td>Takufumi Yanagisawa</td>
<td>Osaka University, Japan</td>
<td></td>
</tr>
<tr>
<td>Roland Zahn</td>
<td>Kings College London, England</td>
<td></td>
</tr>
<tr>
<td>Frank Scharnowski</td>
<td>University of Zurich, Switzerland</td>
<td></td>
</tr>
<tr>
<td>Takashi Yamada</td>
<td>Showa University Karasuyama Hospital, Japan</td>
<td></td>
</tr>
<tr>
<td>Manfred Hallschmid</td>
<td>University of Tübingen, Germany</td>
<td></td>
</tr>
<tr>
<td>Talma Hendler</td>
<td>Tel Aviv University, Israel</td>
<td></td>
</tr>
<tr>
<td>Christian Paret, Gabriele Ende, Christian Schmahl</td>
<td>Central Institute of Mental Health Mannheim, Germany</td>
<td></td>
</tr>
<tr>
<td>Martin Fungisai Gerchen and Peter</td>
<td>Central Institute of</td>
<td></td>
</tr>
<tr>
<td>Kirsch</td>
<td>Mental Health Mannheim, Germany</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>--------------------------------</td>
<td></td>
</tr>
<tr>
<td>Natasza Orlov and Paul Allen</td>
<td>Kings College London, England and</td>
<td></td>
</tr>
<tr>
<td>Mariela Rance</td>
<td>Yale University, USA</td>
<td></td>
</tr>
<tr>
<td>Marina Papoutsi</td>
<td>University College London, England</td>
<td></td>
</tr>
<tr>
<td>Sarah Baumeister and Daniel Brandeis</td>
<td>Central Institute of Mental Health Mannheim, Germany</td>
<td></td>
</tr>
</tbody>
</table>

We would like to acknowledge our funding: The European Union’s Seventh Framework Programme for research, technological development and demonstration, grant agreement 603016 (EU-MATRICS).